BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 9066045)

  • 21. Persistent efficacy of Vi conjugate vaccine against typhoid fever in young children.
    Mai NL; Phan VB; Vo AH; Tran CT; Lin FY; Bryla DA; Chu C; Schiloach J; Robbins JB; Schneerson R; Szu SC
    N Engl J Med; 2003 Oct; 349(14):1390-1. PubMed ID: 14523155
    [No Abstract]   [Full Text] [Related]  

  • 22. Efficacy of purified Vi polysaccharide typhoid vaccine.
    Park JH; Hong JJ; Choi ES; Lee JW; Park JH
    J Vet Sci; 2002 Jun; 3(2):67-70. PubMed ID: 12441674
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Re-examination of immune response and estimation of anti-Vi IgG protective threshold against typhoid fever-based on the efficacy trial of Vi conjugate in young children.
    Szu SC; Klugman KP; Hunt S
    Vaccine; 2014 Apr; 32(20):2359-63. PubMed ID: 24630869
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of two WHO First International Standards for Vi polysaccharide from Citrobacter freundii and Salmonella enterica subspecies enterica serovar Typhi.
    Gao F; Swann C; Rigsby P; Rijpkema S; Lockyer K; Logan A; Bolgiano B;
    Biologicals; 2019 Jan; 57():34-45. PubMed ID: 30502020
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vaccination of active component US military personnel against Salmonella Typhi.
    Porter CK; Sorrell T; Mitra I; Riddle MS
    Vaccine; 2017 Mar; 35(14):1742-1748. PubMed ID: 28268075
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization.
    Klugman KP; Koornhof HJ; Robbins JB; Le Cam NN
    Vaccine; 1996 Apr; 14(5):435-8. PubMed ID: 8735556
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vi capsular polysaccharide: Synthesis, virulence, and application.
    Hu X; Chen Z; Xiong K; Wang J; Rao X; Cong Y
    Crit Rev Microbiol; 2017 Aug; 43(4):440-452. PubMed ID: 27869515
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Constitutive expression of the Vi polysaccharide capsular antigen in attenuated Salmonella enterica serovar typhi oral vaccine strain CVD 909.
    Wang JY; Noriega FR; Galen JE; Barry E; Levine MM
    Infect Immun; 2000 Aug; 68(8):4647-52. PubMed ID: 10899868
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of a bivalent conjugate vaccine candidate against malaria transmission and typhoid fever.
    An SJ; Scaria PV; Chen B; Barnafo E; Muratova O; Anderson C; Lambert L; Chae MH; Yang JS; Duffy PE
    Vaccine; 2018 May; 36(21):2978-2984. PubMed ID: 29681410
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Virulence and immunogenicity of galactose-resistant variants of Salmonella typhi Ty21a.
    Saxena M; Percheson PB; Di Fabio JL
    J Infect Dis; 1993 Aug; 168(2):522-3. PubMed ID: 8336003
    [No Abstract]   [Full Text] [Related]  

  • 31. Impaired antibody response after immunization of HIV-infected individuals with the polysaccharide vaccine against Salmonella typhi (Typhim-Vi).
    Kroon FP; van Dissel JT; Ravensbergen E; Nibbering PH; van Furth R
    Vaccine; 1999 Aug; 17(23-24):2941-5. PubMed ID: 10462227
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Establishment of the first International Standard for human anti-typhoid capsular Vi polysaccharide IgG.
    Rijpkema S; Hockley J; Logan A; Rigsby P; Atkinson E; Jin C; Goldblatt D; Liang H; Bachtiar NS; Yang JS; Goel A; Ramasamy V; Pasetti MF; Pollard AJ;
    Biologicals; 2018 Nov; 56():29-38. PubMed ID: 30201529
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Salmonella enterica serovar Typhi Ty21a expressing human papillomavirus type 16 L1 as a potential live vaccine against cervical cancer and typhoid fever.
    Fraillery D; Baud D; Pang SY; Schiller J; Bobst M; Zosso N; Ponci F; Nardelli-Haefliger D
    Clin Vaccine Immunol; 2007 Oct; 14(10):1285-95. PubMed ID: 17687110
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of vi-tetanus toxoid conjugated typhoid vaccine (PedaTyph™) in Indian children: School based cluster randomized study.
    Mitra M; Shah N; Ghosh A; Chatterjee S; Kaur I; Bhattacharya N; Basu S
    Hum Vaccin Immunother; 2016 Apr; 12(4):939-45. PubMed ID: 26901576
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A bivalent conjugate vaccine containing PspA families 1 and 2 has the potential to protect against a wide range of Streptococcus pneumoniae strains and Salmonella Typhi.
    Kothari N; Kothari S; Choi YJ; Dey A; Briles DE; Rhee DK; Carbis R
    Vaccine; 2015 Feb; 33(6):783-8. PubMed ID: 25545593
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vi-Vaccinations Induce Heterogeneous Plasma Cell Responses That Associate With Protection From Typhoid Fever.
    Cross DL; Verheul MK; Leipold MD; Obermoser G; Jin C; Jones E; Starr JS; Mohorianu I; Blohmke CJ; Maecker HT; Napolitani G; Hill J; Pollard AJ
    Front Immunol; 2020; 11():574057. PubMed ID: 33424833
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Revaccination with locally-produced vi typhoid polysaccharide vaccine among chinese school-aged children: safety and immunogenicity findings.
    Zhou WZ; Koo HW; Wang XY; Zhang J; Park JK; Zhu F; Deen J; Acosta CJ; Chen Y; Wang H; Galindo CM; Ochiai L; Park T; von Seidlein L; Xu ZY; Clemens JD
    Pediatr Infect Dis J; 2007 Nov; 26(11):1001-5. PubMed ID: 17984806
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [A chemical typhoid vaccine containing a surface-antigen complex including the K-antigen].
    Stepanova LK; Belaia IuA; Sergeeva NS; Ageeva VA; Petrukhin VG
    Zh Mikrobiol Epidemiol Immunobiol; 1993; (1):51-6. PubMed ID: 7520650
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The problem of designing typhoid vaccines].
    Tymchuk SN; Boĭchenko MN; Vorob'ev AA
    Zh Mikrobiol Epidemiol Immunobiol; 1996; (4):86-90. PubMed ID: 9027185
    [No Abstract]   [Full Text] [Related]  

  • 40. Multicenter study for the evaluation of the antibody response against salmonella typhi Vi vaccination (EMPATHY) for the diagnosis of Anti-polysaccharide antibody production deficiency in patients with primary immunodeficiency.
    Sánchez-Ramón S; de Gracia J; García-Alonso AM; Rodríguez Molina JJ; Melero J; de Andrés A; García Ruiz de Morales JM; Ferreira A; Ocejo-Vinyals JG; Cid JJ; García Martínez JM; Lasheras T; Vargas ML; Gil-Herrera J; García Rodríguez MC; Castañer JL; González Granado LI; Allende LM; Soler-Palacin P; Herráiz L; López Hoyos M; Bellón JM; Silva G; Gurbindo DM; Carbone J; Rodríguez-Sáinz C; Matamoros N; Parker AR; Fernández-Cruz E;
    Clin Immunol; 2016 Aug; 169():80-84. PubMed ID: 27236002
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.